[company_age]unknown[/company_age][employees]11-50 employees[/employees][funding]Series A[/funding][description]Orthox is a medical technology company founded to commercialize technology developed at Oxford University. Their mission is to revolutionize the treatment of cartilage injuries through their unique hydrogel implant, FibroFix™. This implant offers a compelling solution for the millions of patients suffering from joint damage by achieving both tissue regeneration and functional replacement. Orthox's initial focus is on the knee, but they plan to expand to other joints and develop pipeline products beyond orthopedics. Their target market includes both B2C and B2B segments, with a focus on patients suffering from cartilage damage and the medical professionals who treat them. Orthox's technology stands out due to its exceptional strength, resilience, and regenerative properties, making it a unique offering in the market.[/description][ps]FibroFix™ Cartilage, a dry, porous implant that is stored and inserted by the surgeon in a minimally invasive procedure.[/ps]